ESTRO 2024 - Abstract Book

S2296

Clinical - Urology

ESTRO 2024

A significant drop in the PSA value was identified after 3 months of treatment (2.24ng/ml vs 0.65ng/ml, p-value = 0.004) and after 6 months (2.24ng/ml vs 0.12ng/ml, p-value = 0.019) (Figure 1). Moreover, a significant increase in the risk of relapse is found in patients with castration-resistant cancer (HR = 10.49; CI95% [2.902; 37.901]; p < 0.0005).

Thirteen patients (18.3%) experienced acute toxicity, primarily characterized as mild pain in nine cases and Grade 1 gastrointestinal toxicity in two cases, along with Grade 1 asthenia in two additional cases. Chronic toxicity was observed in three patients (4%), with no instances of Grade 4 toxicity detected.

Conclusion:

SBRT is a viable option for oligometastatic patients due to its excellent local and biochemical control with a negligible toxicity profile. The rate of distant progression means that the role of SBRT must be reassessed with the aim of delaying systemic therapy or as part of a combination treatment.

Keywords: SBRT, prostate, oligometastasis